271 related articles for article (PubMed ID: 18424725)
1. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
[TBL] [Abstract][Full Text] [Related]
2. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
[TBL] [Abstract][Full Text] [Related]
4. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
Jayaprakash P; Ai M; Liu A; Budhani P; Bartkowiak T; Sheng J; Ager C; Nicholas C; Jaiswal AR; Sun Y; Shah K; Balasubramanyam S; Li N; Wang G; Ning J; Zal A; Zal T; Curran MA
J Clin Invest; 2018 Nov; 128(11):5137-5149. PubMed ID: 30188869
[TBL] [Abstract][Full Text] [Related]
5. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
6. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
8. Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.
Jachetti E; Cancila V; Rigoni A; Bongiovanni L; Cappetti B; Belmonte B; Enriquez C; Casalini P; Ostano P; Frossi B; Sangaletti S; Chiodoni C; Chiorino G; Pucillo CE; Tripodo C; Colombo MP
Cancer Immunol Res; 2018 May; 6(5):552-565. PubMed ID: 29523597
[TBL] [Abstract][Full Text] [Related]
9. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
10. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD
J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630
[TBL] [Abstract][Full Text] [Related]
11. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
Liu Z; Guo B; Lopez RD
J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
13. Gammadelta T cells assist alphabeta T cells in the adoptive transfer of contact hypersensitivity to para-phenylenediamine.
Yokozeki H; Watanabe K; Igawa K; Miyazaki Y; Katayama I; Nishioka K
Clin Exp Immunol; 2001 Sep; 125(3):351-9. PubMed ID: 11531941
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
15. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.
Jenq RR; Curran MA; Goldberg GL; Liu C; Allison JP; van den Brink MR
PLoS One; 2012; 7(4):e35222. PubMed ID: 22493742
[TBL] [Abstract][Full Text] [Related]
16. Gamma delta T cells provide an early source of interferon gamma in tumor immunity.
Gao Y; Yang W; Pan M; Scully E; Girardi M; Augenlicht LH; Craft J; Yin Z
J Exp Med; 2003 Aug; 198(3):433-42. PubMed ID: 12900519
[TBL] [Abstract][Full Text] [Related]
17. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
19. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.
Yi H; Yu X; Guo C; Manjili MH; Repasky EA; Wang XY
Cancer Immunol Immunother; 2011 Mar; 60(3):349-60. PubMed ID: 21088965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
